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Gastrin-releasing peptide receptors (GRPRs) are overexpressed in prostate cancer and are suitable for targeted radionuclide
therapy (TRT). We optimized the bombesin-derived GRPR-antagonist PEG2-RM26 for labeling with
177Lu and further determined
the effect of treatment with 177Lu-labeled peptide alone or in combination with the anti-HER2 antibody trastuzumab in a
murine model. The PEG2-RM26 analog was coupled to NOTA, NODAGA, DOTA and DOTAGA chelators. The peptide-chelator
conjugates were labeled with 177Lu and characterized in vitro and in vivo. A preclinical therapeutic study was performed in PC-3
xenografted mice. Mice were treated with intravenous injections (6 cycles) of (A) PBS, (B) DOTAGA-PEG2-RM26, (C)
177Lu-
DOTAGA-PEG2-RM26, (D) trastuzumab or (E)
177Lu-DOTAGA-PEG2-RM26 in combination with trastuzumab.
177Lu-DOTAGA-PEG2-
RM26 demonstrated quantitative labeling yield at high molar activity (450 GBq/μmol), high in vivo stability (5 min pi >98% of
radioligand remained when coinjected with phosphoramidon), high afﬁnity to GRPR (KD = 0.4  0.2 nM), and favorable
biodistribution (1 hr pi tumor uptake was higher than in healthy tissues, including the kidneys). Therapy with 177Lu-DOTAGA-
PEG2-RM26 induced a signiﬁcant inhibition of tumor growth. The median survival for control groups was signiﬁcantly shorter
than for treated groups (Group C 66 days, Group E 74 days). Trastuzumab together with radionuclide therapy signiﬁcantly
improved survival. No treatment-related toxicity was observed. In conclusion, based on in vitro and in vivo characterization of
the four 177Lu-labeled PEG2-RM26 analogs, we concluded that
177Lu-DOTAGA-PEG2-RM26 was the most promising analog for
TRT. Radiotherapy using 177Lu-DOTAGA-PEG2-RM26 effectively inhibited tumor growth in vivo in a murine prostate cancer
model. Anti-HER2 therapy additionally improved survival.
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Abbreviations: ADT: androgen deprivation therapy; CRPC: castration-resistant prostate cancer; DOTA: 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid; DOTAGA: 1,4,7,10-tetraazacyclododececane-1-(glutaric acid)-4,7,10-triacetic acid; EGF: epidermal growth factor;
GRPR: gastrin-releasing peptide receptor; HER2 (1,3): human epidermal growth factor receptor type 2 (1,3); HPLC: high-performance liquid
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xymethyl-1,4,7-triazacyclononane; NOTA: 1,4,7-triazacyclononane-N,N0,N00-triacetic acid; PA: phosphoramidon (neprilysin (NEP)-inhibitor);
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Introduction
Prostate cancer is the most frequently diagnosed cancer and the
second leading cause of cancer-related death in men. Similar to
other cancers, over 90% of prostate cancer-related deaths are
due to widespread metastatic disease. With the recent advance-
ments in molecular imaging, metastatic prostate cancer patients
can be classiﬁed into different prognostic subgroups depending
on the metastatic spread, such as oligometastatic, poly-
metastatic or oligorecurrent cancers.1 These subgroups have a
different progression course and can beneﬁt from improved
personalized treatment strategies directed against speciﬁc fea-
tures of the pathology.
A promising therapeutic approach is the use of radio-
labeled probes for targeted radionuclide therapy (TRT). TRT
is based on the use of high-afﬁnity radiolabeled molecules
designed to bind to molecular targets on the surface of tumor
cells. This allows the selective delivery of systemically admin-
istered radioactivity to cancer cells while limiting radiation
exposure to healthy tissues. An additional advantage of TRT,
especially in the context of the highly heterogeneous nature of
prostate cancer, is the ability to hit tumor cells that do not
express the targeted receptor via the crossﬁre effect.
Peptides are attractive vehicles for TRT because of their
rapid clearance, fast tumor penetration, low immunogenicity,
inexpensive production and well-established bioconjugation
and radiolabeling strategies. The successful introduction of
somatostatin analogs for peptide receptor-mediated TRT in
neuroendocrine tumors2 paved the way for other radiopeptides
targeting G-protein-coupled receptors, such as bombesin ana-
logs targeting gastrin-releasing peptide receptors (GRPRs)
overexpressed on tumor cells.
GRPRs have been found to be overexpressed in primary
prostate cancer (63–100%), lymph node metastases (86%) and
bone metastases (53%) but not in the hyperplastic prostate.3,4
Importantly, GRPRs are highly expressed in the early stages of
prostate cancer, therefore emerging as attractive targets for
therapies directed against the oligometastatic state of prostate
cancer—a transient step in the metastatic process between
localized disease and widespread metastases. Bombesin is an
amphibian linear tetradecapeptide with a high afﬁnity for the
human GRPRs. Several derivatives of bombesin have been
developed over the past decades for diagnostic and/or therapeu-
tic purposes. The ﬁeld was initially focused on bombesin ago-
nists due to the rapid radioligand internalization.5 However, the
superior results reported for somatostatin antagonists6 led to a
change of paradigm in the development of bombesin analogs
toward potent GRPR-antagonists.7
We have recently investigated several constructs based
on the GRPR-antagonist RM26 [(D-Phe6,Sta13,Leu14-NH2)
bombesin(6–14)].8,9 It is known that pharmacokinetics and target-
ing properties of small peptides and proteins may be altered by
structural modiﬁcations.10 Therefore, we investigated the inﬂuence
of different length of PEG linkers (n = 2, 3, 4, 6) and different
chelating moieties (NOTA, NODAGA, DOTA, DOTAGA) on
the in vivo imaging properties of resulting radioligands. The effects
of the PEG spacer’s length on overall hydrophilicity were found to
be minor.11 However, the use of different macrocyclic chelators
had a profound inﬂuence on the biodistribution proﬁle of the radio-
labeled conjugates.12,13 In this regard, both the geometry and the
net charge of the radionuclide–chelator complex were identiﬁed as
important factors inﬂuencing the blood clearance, activity uptake in
tumors and normal organs, and kidney activity retention.
The optimal chelator–radionuclide pair resulted in exception-
ally high tumor-to-organ ratios suggesting that X-PEG2-RM26
could be exploited for TRT against GRPR using a therapeutic
radiometal such as lutetium-177. Lutetium-177 is a β−-emitter
with half-life of 6.71 days and maximum energy of 0.5 MeV,
resulting in a maximal tissue penetration of <2 mm, most suitable
for irradiation of small lesions. The accompanying gamma pho-
tons (113 keV, 6.4% and 208 keV, 11%) of 177Lu allow for single
photon emission computed tomography (SPECT) acquisition,
favoring the application of this attractive radioisotope in a
theranostic setting.14 A systematic search for the most suitable
chelator for coupling to the biomolecule of interest, namely PEG2-
RM26, is expected to help optimize the ﬁnal radioligand proﬁle.
In addition to the great potential of GRPR-targeting radiotherapy
approaches, the opportunity to further improve therapeutic index
via combination therapies should be investigated. These combina-
tion therapies often consist of simultaneous application of different
mechanisms of action and have been increasingly implemented in
the clinic in the past years, showing superior results over mono-
therapies. Initially, prostate cancer is hormone-dependent and hence
androgen deprivation therapy (ADT) generally leads to transient
remissions. However, patients will eventually develop resistance to
ADT and experience disease progression towards castration-
resistant prostate cancer (CRPC) which is highly resistant to cyto-
toxic drugs and is invariably fatal.15,16 Progression of CRPC is often
driven by growth factors and their receptors, and abnormal levels of
growth factors have been observed in tissue specimens collected
from prostate cancer patients.17 The epidermal growth factor
What’s new?
Targeted radionuclide therapy (TRT) using radiolabeled peptides seeking gastrin-releasing peptide receptors (GRPRs) in tumors
is a promising approach to treat disseminated prostate cancer. The possibility to improve the therapeutic index via
combination therapies also warrants further investigation. Here, the authors developed and characterized a promising GRPR-
targeting radioligand and demonstrated its therapeutic efﬁcacy in prostate cancer xenografts. Moreover, this study using the
anti-HER2 antibody trastuzumab presents the ﬁrst in vivo proof-of-principle that the effects of anti-GRPR radiotherapy can be
ampliﬁed by co-administration of anti-HER2 treatment leading to prolonged survival.
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receptors (EGFR) family plays important roles in regulating cell
proliferation, survival and differentiation, acting through ErbB or
HER receptors including EGFR (HER1 or ErB-1), HER2/neu
(ErbB-2), HER3 (ErbB-3) and HER4 (ErbB-4). Likewise, abnor-
mal expression and activity of some of these receptors have been
reported in prostate cancer. Most notably, HER-2/neu was shown
to be overexpressed and to have an important role in the develop-
ment of castration-resistant disease.18,19
In a recent study, Andersson et al. showed that HER-2/neu
expression in androgen-independent PC-3 prostate cancer cells
signiﬁcantly increased after external irradiation leading to resis-
tance to therapy.20 The subsequent postirradiation treatment
with the anti-HER-2/neu monoclonal antibody trastuzumab
resulted in a twofold decrease in the PC-3 cell survival in vitro.
Therefore, we hypothesized that the inhibition of this
prosurvival signaling pathway could amplify tumor response
to TRT.
The aim of our study was to determine the factors inﬂuencing
the effects of treatment with the 177Lu-labeled GRPR-antagonist
PEG2-RM26 in a murine model. To reach this goal, we ﬁrst inves-
tigated the inﬂuence of chelators on the labeling, stability, binding
afﬁnity and biodistribution proﬁle of 177Lu-labeled PEG2-RM26
and identiﬁed the most suitable construct for the subsequent
GRPR-TRT. In vivo degradation of radiopeptides by proteolytic
enzymes can limit their successful application as theranostic pro-
bes. Therefore, in our study, we have also evaluated the inﬂuence
of the neprilysin (NEP) inhibitor phosphoramidon (PA) on the
stabilization of radiopeptides in vivo. Finally, we explored if HER-
2/neu could be targeted concomitantly with GRPRs in our model
thereby improving therapeutic outcome.
Materials and Methods
Detailed descriptions of materials, equipment and methods
used in our study are given in the Supporting Information
The synthesis of X-PEG2-RM26 (X = NOTA, NODAGA,
DOTA, DOTAGA) by solid-phase peptide synthesis (SPPS)
was previously reported12 (Supporting Information Fig. S1).
No carrier added 177LuCl3 was purchased from Curium
Pharma and ITG Isotopes Technologies Garching GmbH. In
vitro cell studies were performed using PC-3 human prostate
adenocarcinoma cells expressing the GRPR (ATCC, LGC
Promochem).
Data were analyzed by an unpaired, two-tailed t-test or
one-way ANOVA with Bonferroni correction for multiple
comparisons using GraphPad Prism (version 7.03 for Win-
dows GraphPad Software, La Jolla, CA) to determine signiﬁ-
cant statistical differences (p < 0.05).
Labelings of X-PEG2-RM26 for in vitro and in vivo evalua-
tion is described in details in the Supporting Information. High
molar activity labeling studies (≈300 MBq/nmol) were per-
formed using 1.3 nmol of DOTAGA-PEG2-RM26 in 40 μl of
1 M ascorbic acid pH 5.5, followed by incubation with 177Lu-
chloride at 85C for 30 min. The activity concentration of
177Lu solution used for labeling was ≈400 MBq/30 μl. The
radiochemical yield was determined by instant thin-layer chro-
matography (ITLC) and high-performance liquid chromatogra-
phy (HPLC). Labeling stability was evaluated in murine serum.
In vitro binding speciﬁcity, cellular processing and kinetics
of binding to and dissociation from living cells were evaluated
using PC-3 cells as previously described.13
Animal experiments were planned and performed in accor-
dance with the national legislation on the protection of labo-
ratory animals, and the study plans were approved by the
local committee for animal research ethics. BALB/c nu/nu
mice bearing PC-3 xenografts were used for in vivo studies.
The in vivo metabolic stability of radioligands without or with
coinjection of PA was evaluated in healthy male Swiss albino
mice (30  5 g, NCSR “Demokritos” Animal House Facility)
5 min pi of 177Lu-X-PEG2-RM26 (X = NODAGA, DOTA,
DOTAGA) based on previously reported methods.21
For comparative biodistribution studies, mice were injected with
50 pmol (120 kBq, 100 μl) of 177Lu-X-PEG2-RM26 (X =
NODAGA, DOTA, DOTAGA) and euthanized at 1 and 24 hr
pi. The inﬂuence of coinjection of PA on the biodistribution of
177Lu-DOTAGA-PEG2-RM26 (88 kBq, 100 μl) at 50 pmol total
peptide dose was studied at 1 hr pi. To investigate the inﬂuence of
injected peptide dose on tumor targeting and biodistribution proﬁle
at 1 hr pi of 177Lu-DOTAGA-PEG2-RM26, the administrated pep-
tide dose was adjusted to 50, 100, 250, 500 and 750 pmol. Bio-
distribution of 177Lu-DOTAGA-PEG2-RM26 (80 kBq, 100 μl)
overtime at the 100 pmol peptide dose was studied in the time inter-
val between 30 min and 92 hr pi. Activity distribution on tumor sec-
tions was evaluated using receptor autoradiography. In vitro and
in vivo HER2 expression in PC-3 cells was conﬁrmed using 68Ga-
labeled ABY-025, a second-generation afﬁbody scaffold protein with
a high afﬁnity toHER2 receptor.22
Estimation of the organs’ absorbed doses was done for the
injection of 100 pmol of 177Lu-DOTAGA-PEG2-RM26, using
the biodistribution data over time and a MOBY-phantom
based dosimetry model.23 Dosimetry estimates were made for
other peptide masses by using the ratios in the 1 hr uptake
values at 50–250 pmol with the 100 pmol 1 hr uptake data
(Supporting Information Fig. S2). Tumor control probability
was compared for tumors of 200 and 100 mm3 for protocols
including six therapy cycles within 2 weeks, using the PC-3
radiation sensitivity parameters, derived from Carlson et al.24
Experimental in vivo therapy
For in vivo therapy, ﬁve experimental groups (n = 11–12) were
treated every second day for 2 weeks (6 cycles): Group A with PBS;
Group B with DOTAGA-PEG2-RM26 (200 pmol); Group C with
177Lu-DOTAGA-PEG2-RM26 (200 pmol/60 MBq); Group D with
trastuzumab (5 mg/kg); Group E with 177Lu-DOTAGA-PEG2-
RM26 (200 pmol/60 MBq) in combination with trastuzumab
(5mg/kg). Average tumor size was 105  28 mm3. Groups B, C and
Ewere coinjected with PA (300 μg/mouse). Tumor uptake of activity
was followed during treatment by single photon emission computed
tomography/computed tomography (SPECT/CT) imaging on days
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14, 16 and 25. One week after accomplished treatment, two
animals/group were sacriﬁced; blood was collected for leukocyte
counting and tumor, liver, kidneys and pancreas were taken for
histological examination. The mice were monitored two times
weekly. Mice were euthanized when they lost more than 15% of
their original mass, when tumor ulceration occurred or when
tumor volume exceeded 1 cm3. At end point, tumors, kidneys,
liver and pancreas were collected and histologically evaluated
(n = 3, the longest survivals).
Results
Radiolabeling
Radiolabeling of X-PEG2-RM26 with
177Lu was achieved in high
yields (Table 1). Because of the high radiolabeling yields obtained
for NODAGA, DOTA and DOTAGA-containing analogs, these
tracers were used without puriﬁcation for further experiments. An
in vitro serum stability test revealed very good serum stability for
177Lu-DOTA-PEG2-RM26 and
177Lu-DOTAGA-PEG2-RM26 with
less than 1.5% free radiometal release after 1 hr incubation at 37C.
A higher activity release was observed for 177Lu-NODAGA-PEG2-
RM26. The pronounced release of 177Lu observed for 177Lu-
NOTA-PEG2-RM26, indicated a poor radiometal–chelate complex
stability for this analog.
For therapy, 177Lu-DOTAGA-PEG2-RM26 was successfully
labeled with 177Lu in a higher than 99.5% radiolabeling yield
at a maximum molar activity of 450 MBq/nmol (Supporting
Information Fig. S3).
In vitro studies
Binding of 177Lu-X-PEG2-RM26 to GRPR-expressing PC-3 cells
was signiﬁcantly reduced by presaturation of receptors with excess
of nonlabeled peptide, indicating receptor-mediated binding
(Supporting Information Fig. S4). The binding of all analogues was
rapidly reaching approximately 70% of maximum cell-associated
activity after 1 hr incubation (Supporting Information Fig. S5). The
cell-associated radioactivity reached a plateau after 4 hr for all con-
jugates with the exception of 177Lu-DOTAGA-PEG2-RM26 where
it gradually increased up to the 24 hr time-point. The internaliza-
tion pattern was similar for all analogs showing a low fraction of
internalized radioactivity typical for GRPR-antagonists that could
be explained by cell surface renewal. The measurements of binding
kinetics of 177Lu-X-PEG2-RM26 in real time showed sub-
nanomolar equilibrium dissociation constant (KD) values for all
analogs (Table 1).
The presence of HER-2/neu on PC-3 cells in vitro was con-
ﬁrmed by a binding speciﬁcity assay using 68Ga-labeled anti-
HER2 afﬁbody ABY025 (Fig. 5a).
In vivo studies
In vivo metabolic stability of 177Lu-X-PEG2-RM26 (X = NODAGA,
DOTA, DOTAGA). Metabolic stability was tested for 177Lu-X-
PEG2-RM26 (X = NODAGA, DOTA, DOTAGA) in Swiss albino
mice (Table 1, Supporting Information Fig. S6). The NOTA-
modiﬁed conjugate was excluded from in vivo characterization
due to poor in vitro stability of the radiometal-chelate. The in vivo
formation of radiometabolites was studied by HPLC analysis of
mouse blood samples collected at 5 min after injection of test-
radiopeptide alone or coinjected with PA (Supporting Information
Fig. S6). Within this period, 177Lu-DOTAGA-PEG2-RM26
exhibited the highest in vivo stability. Upon coinjection of PA, the
stability of all tested radiopeptides increased signiﬁcantly.
Comparative biodistribution of 177Lu-X-PEG2-RM26 (X = NODAGA,
DOTA, DOTAGA) in PC-3 tumor-bearing mice. A comparative
biodistribution study was performed in PC-3 xenografted mice
at 1 and 24 hr pi to determine which of the radiolabeled conju-
gates is the most suitable for therapy (Figs. 1a and 1b, Supporting
Information Table S1). Lumbar lymph nodes metastases were
detected in this batch of animals and were collected from all mice.
All analogs demonstrated rapid blood clearance. The body clear-
ance was predominantly renal with low kidney retention for all
tested radiopeptides at 1 hr pi. Radioactivity uptake in tumors
and metastases exceeded uptake in all normal organs including
excretory organs for all variants with the exception of pancreatic
uptake for the NODAGA-modiﬁed analog. Activity uptake in
tumors was signiﬁcantly higher for DOTA and DOTAGA-
carrying radioligands than for the NODAGA one. The activity
uptake in tumors decreased by twofold at 24 hr pi. However,
clearance of activity from blood and normal organs was faster
Table 1. Labeling yield (molar activity 3 MBq/nmol), metal-chelate stability in serum, GRPR binding affinity and in vivo metabolic stability of
177Lu-X-PEG2-RM26 (X = NOTA, NODAGA, DOTA and DOTAGA); in vivo metabolic stability determined in peripheral mouse blood collected at
5 min pi of test radioligand without or with coinjection of PA
NOTA NODAGA DOTA DOTAGA
Labeling yield, % 96  3 (19) 99.4  0.6 (24) 99.9  0.2 (24) 99.8  0.3 (28)
177Lu-release, 37C 1 hr in plasma 16  2% (3) 4.3  0.7% (3) 1.5  0.2% (3) 1.6  0.5% (3)
GRPR-binding affinity, KD, pM 331  95 (3) 225  50 (3) 211  88 (3) 431  240 (3)
Intact radiopeptide, 5 min pi n.a. 64  2% (3) 65  5% (3) 71  3% (3)
Intact radiopeptide, 5 min pi
(+ phosphoramidon)
n.a. >96%1 (2) >96.5%1 (2) >98%1 (2)
Data are presented as average  standard deviation.
Values in parentheses represent the number of experiments.
1Values are not significantly different.
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than from tumors (Fig. 1b, Supporting Information Tables S1
and S2). 177Lu-NODAGA-PEG2-RM26 had the least favorable
biodistribution proﬁle at 1 hr pi with the lowest uptake in tumor
and metastases and the highest radioactivity accumulation in liver
and GRPR-expressing organs. Additionally, renal uptake was
higher for this analog.
Inﬂuence of the NEP-inhibitor PA on the biodistribution of
177Lu-DOTAGA-PEG2-RM26. A biodistribution study was per-
formed in PC-3 xenograftedmice to determine the inﬂuence of PA-
coinjection on activity uptake in tumors and normal organs
(Figs. 1c and 1d, Supporting Information Table S3). Treatment with
PA had a prominent impact on the uptake of 177Lu-DOTAGA-
PEG2-RM26 (50 pmol) in tumor and inGRPR-expressing pancreas
at 1 hr pi, presumably as a result of increased stabilization in blood
circulation. In this regard, the tumor uptake increased 1.6-fold while
pancreatic uptake increased threefold, resulting in a decrease in
tumor-to-pancreas ratio. Coinjection of PA had no effect on kidney
uptake. Consequently, tumor-to-kidney ratios have increased
1.4-fold. Delivering a high radioactivity dose to the notoriously
radioresistant solid tumors is highly important, therefore further
in vivo evaluation and therapy were performedwith PA coinjection.
Inﬂuence of injected peptide mass on the biodistribution of
177Lu-DOTAGA-PEG2-RM26. In order to identify the optimal
injected peptide dose, a comparative biodistribution study was per-
formed at 1 hr pi of 177Lu-DOTAGA-PEG2-RM26 in a total peptide
range 50–750 pmol (Fig. 2, Supporting Information Table S4).
A strong blocking effect could be observed in tumors and GRPR-
expressing organs with increasing peptide dose. Tumor uptake
decreased threefold for 750 pmol in comparison to 50 pmol. Uptake
in kidney and non-GRPR expressing organs was not inﬂuenced by
injected peptide dose. As a result, tumor-to-kidney ratios decreased
twofold for 750 pmol compared to 50 pmol (Fig. 2b, Supporting
Information Table S5). However, autoradiography results indicated
that despite superior uptake, tumor penetration was insufﬁcient for
the 50 pmol injected dose with most of the radioactivity located in
the rim of the tumor (Fig. 2c). Activity distribution in tumors was
homogeneous after injection of 100–250 pmol.
Biodistribution of 177Lu-DOTAGA-PEG2-RM26 over time. Data
on the biodistribution of 177Lu-DOTAGA-PEG2-RM26 (100 pmol)
in the period 0.5–90 hr pi are presented in Figure 3 and Supporting
Information Table S6. 177Lu-DOTAGA-PEG2-RM26 displayed a
rapid clearance from blood and background tissues. Tumor uptake
Figure 1. (a, b) Biodistribution of 177Lu-X-PEG2-RM26 (X = NODAGA, DOTA and DOTAGA) in PC-3 xenografted BALB/C nu/nu mice at 1 and
24 hr pi, respectively (50 pmol, 88 kBq/animal; mouse weight 15  1 g; tumor weight 0.7  0.2 g. (c) Inﬂuence of coadministration of PA on
the biodistribution of 177Lu-DOTAGA-PEG2-RM26 in PC-3 xenografted BALB/C nu/nu mice at 1 hr (mouse weight 16  2 g; tumor weight
0.17  0.05 g). (d) Tumor-to-normal-tissue ratios at 1 hr.
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peaked at 1 hr pi but decreased fourfold at 24 hr pi. The retention
of radioactivity in the kidneys was low and a rapid decrease was
observed within 24 hr pi. Tumor-to-kidney ratios increased three-
fold from 0.5 hr pi up to 4 hr pi (Fig. 3b, Supporting Information
Table S7). With time, due to the release of activity from tumors,
tumor-to-kidney ratios decreased up to 90 hr pi. Nonetheless,
tumor-to-kidney ratios were over 2 at all time-points. Autoradiog-
raphy of tumor sections revealed a homogeneous uptake in tumors
at all time-points and a slow washout of radioactivity from the
tumor core (Fig. 3c).
Dosimetry. It was found that the protocol including six injec-
tions of 200 pmol/60 MBq of 177Lu-DOTAGA-PEG2-RM26
within 2 weeks should give good tumor control probability
(Supporting Information Figs. 7A and S7B). Tumors with a size
of 100 mm3 should respond better to treatment compared to
larger, 200 mm3 tumors. The estimated absorbed doses per
60 MBq treatment cycle would be 11 Gy to the tumor, 5 Gy to
the kidneys and 12 Gy to pancreas (Supporting Information
Figs. S7C and S7D).
Therapy. The results of the in vivo therapy study are presented
in Figure 4. Tumor growth was slower in both groups treated
with radiolabeled peptide than in the control groups already after
three therapy cycles (Fig. 4a). Tumor volumes were signiﬁcantly
smaller in treated groups compared to control group when ther-
apy was accomplished (p < 0.05). However, there was no signiﬁ-
cant difference in tumor volumes between the groups treated
with and without trastuzumab throughout the experiment. The
majority of mice were sacriﬁced when tumors reached the maxi-
mum permitted volume or mice began to lose weight when tumor
volume exceeded 0.75 cm3, with few exceptions. Speciﬁcally, three
mice had to be sacriﬁced due to critical weight loss (Groups A, C
and D) and one due to tumor ulceration (Group D).
Figure 2. (a) Comparative biodistribution of different injected peptide doses (80 kBq in 50, 100, 250, 500 and 750 pmol/animal) of 177Lu-
DOTAGA-PEG2-RM26 in BALB/C nu/nu mice bearing PC-3 tumors at 1 hr pi (mouse weight 17  2 g; tumor weight 0.19  0.06 g). (b) Tumor-
to-normal-tissue ratios at 1 hr pi (50, 100, 250, 500 and 750 pmol/animal). (c) Ex vivo GRPR-autoradiography of tumor slices of mice bearing
PC-3 tumors after the injection of 177Lu-DOTAGA-PEG2-RM26 (80 kBq in 50, 100, 250, 500 and 750 pmol) at 1 hr pi. (d) Uptake of activity in
tumor and kidneys as a function of injected peptide dose.
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Mice treated with unlabeled DOTAGA-PEG2-RM26 or tras-
tuzumab alone had the same median survival as the mice in vehicle
group. Therapy with 177Lu-DOTAGA-PEG2-RM26 induced a sig-
niﬁcant prolongation of median survival for Group C compared to
control Groups A, B and D (p < 0.0001). Coinjection of trast-
uzumab with radiolabeled peptide further improved median sur-
vival signiﬁcantly (p < 0.05 for Groups C vs. E; Fig. 4b).
SPECT/CT scans acquired on days 14, 16 and 25 (after
ﬁrst, second and sixth injections) revealed a high initial uptake
of radioactivity in GRPR-expressing tumors, followed by a
pronounced decrease by the end of treatment (Fig. 4d).
Treatment was well tolerated, no weight loss or other signs
of acute toxicity were detected (Fig. 4c). Follow up observa-
tions also did not detect any sign of toxicity, with the excep-
tion of some decrease in body weight in Groups A, B and D
close to the end of the experiment. One week after the last
cycle of therapy, two mice in each group were examined on
leukocyte counts. Measured counts were within a narrow
range for all groups (1.5–2.4 × 109/l).
Histological examination of kidneys, liver and pancreas was
performed for mice sacriﬁced 1 week after therapy (2 mice/group)
and mice with the longest survival time (3 mice/group). The
liver, kidneys and pancreas did not show lesions that could be
attributed to toxicity, and there were no speciﬁc histological
differences between these organs in the different groups of the
experiment.
Histological examination of tumors conﬁrmed their localiza-
tion in the dermis directly under the epidermis. The neoplastic
cells were generally large, growing in a solid pattern and displayed
obvious features of high malignancy (high pleomorphism, pro-
nounced anisokaryosis, nuclear atypia, megalokaryosis, highly
lobulated nuclei or polykaryons and high anaplasia). Mitotic
activity was high with frequent atypical mitotic ﬁgures. There
were extensive areas of necrosis in tumors harvested at end-
point and half of the animals in all groups at this point had
metastases in the abdomen at varying sites: the capsule of the
pancreas, liver and kidney, and the hepatic hilus. Metastases
were not found within the parenchyma of the organs. Neither
Figure 3. (a) Biodistribution of 177Lu-DOTAGA-PEG2-RM26 (80 kBq, 100 pmol/animal) over time (0.5, 1, 2, 4 and 24 hr pi) in PC-3-xenografted
BALB/c nu/nu mice. (b) Tumor-to-normal-tissues ratios at 0.5, 1, 2, 4 and 24 hr pi (mouse weight 17  2 g; tumor weight 0.2  0.1 g). (c) Ex
vivo GRPR-autoradiography of tumor slices of mice bearing PC-3 tumors after the injection of 177Lu-DOTAGA-PEG2-RM26 (100 pmol) at 1, 4
and 24 hr pi. (d) Uptake of activity in tumor and kidneys up to 90 hr pi.
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Figure 4. (a, b, c) The results of the in vivo therapy study in mice
treated with: PBS (black line); nonlabeled peptide (DOTAGA-PEG2-RM26,
200 pmol; teal line); 177Lu-DOTAGA-PEG2-RM26 (60 MBq/200 pmol; red
line); trastuzumab (5 mg/kg; purple line); 177Lu-DOTAGA-PEG2-RM26
(60 MBq/200 pmol) in combination with trastuzumab (5 mg/kg; green
line). (d) Representative SPECT/CT scans of 177Lu-DOTAGA-PEG2-RM26
treated mice (red and green line). Mice were imaged 3 hr pi after ﬁrst,
second and six injections (from top). SPECT/CT images are presented
as MIP in RGB color scale. Abbreviations: K, kidneys; UB, urinary
bladder; T, tumor; P, pancreas.
tumors nor metastases had any pattern speciﬁc to the different
treatments.
Immunohistochemical (IHC) examination of tumors in con-
trol group conﬁrmed HER2 expression in PC-3 xenografts both
at the start and the end of the experiment. These results were in
agreement with PET imaging of HER2 expression using
68Ga-ABY-025 (Fig. 5, Supporting Information Figs. S8 and
S9). Weak membranous staining was detected in broad tumor
areas in the control group. Similar pattern of HER2 expression
was detected in the group treated with nonlabeled peptide. In
the group treated with 177Lu-labeled peptide, staining was
more intensive after treatment but returned to weak with time
(it should be noted that only limited tumor material was available
in animals sacriﬁced after treatment; Fig. 5c). In the groups
treated with trastuzumab at both time points, no HER2 expres-
sion was detected.
Discussion
Recent progress in the treatment of metastatic prostate cancer
applying TRT (e.g. PSMA-targeting therapy using the beta-
emitter lutetium-177 or the alpha-emitter actinium-22524,25)
indicates that TRT might be utilized at earlier stages of prostate
cancer. Success of TRT depends on many factors: the expression
level of the molecular target in the lesion and healthy organs,
the nature of the targeting molecule, its biodistribution pattern
and excretion pathway, its pharmacokinetics and their
matching to the physical properties of radioisotope employed as
well as the size of targeted lesions. Taking into account the com-
plexity of mechanisms driving cancer development and pro-
gression, it is reasonable to assume that TRT combined with
therapies enhancing radiosensitivity should improve treatment
outcome.26
Shifting of TRT toward oligometastatic prostate cancer
might require reconsidering of the molecular target for therapy
due to lower expression of PSMA at earlier stages of prostate
cancer and its high expression in normal tissues (particularly in
salivary and lacrimal glands and kidneys). Xerophthalmia and
xerostomia are often side effects of TRT using PSMA inhibitors
labeled with alpha- and beta-emitting radionuclides, which are
the most suitable for oligometastatic disease.25,27 The high
expression levels of GRPR in the early stages of prostate cancer
indicate that this receptor could be a promising supplementary
molecular target for the treatment of oligometastatic prostate
cancer.3
Short peptides based on natural ligands are attractive targeting
agents for radiotherapy due to their rapid tissue penetration and
rapid blood clearance. However, care should be taken (i) to
achieve high in vivo stability to endogenous proteases, (ii) to avoid
high renal reabsorption and (iii) to limit adverse effects elicited
after binding and activation of the GRPR. Analogs of the GRPR-
antagonist [D-Phe6,Sta13,Leu14-NH2]bombesin(6–14) recently
attracted attention as new molecular tools for TRT of prostate
cancer. The above GRPR-antagonist was coupled with the DOTA
chelator via different linkers and labeled with therapeutic radio-
metals, such as lutetium-1772,28 or yttrium-90.29 In all studies, a
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Figure 5. (a) In vitro binding speciﬁcity of anti-HER2 afﬁbody molecule 68Ga-ABY025 to PC-3 cells. Blocked cells were pretreated with a
100-fold excess of nonlabeled protein 10 min prior to the addition of 1 nM radiolabeled compound. Data are presented as the mean value of
three dishes  SD. (b) PET/CT imaging of HER2 expression in PC-3 xenografted mice at 2 hr pi. The mice were injected with 1 μg (0.2 MBq),
left mouse, or a blocking dose (300 μg, 0.2 MBq), right mouse, of 68Ga-labeled anti-HER2 afﬁbody ABY025. PET/CT images are presented as
MIP in RGB color scale. Abbreviations: K, kidneys; UB, urinary bladder; T, tumor. (c) Immunohistochemical staining of HER2 expression of
4 μm sections of parafﬁnated tissue samples of PC-3 xenografts. Samples were taken 1 week after therapy (left column) and at endpoint
(right column).
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signiﬁcant delay of tumor growth was observed in animals
treated with the radiopeptide. In the present work, we have
modiﬁed the same GRPR-antagonist RM26 by coupling tri-
and tetra-aza macrocyclic chelators to its N-terminus via a
PEG2-linker and investigated the respective
177Lu-labeled
radiopeptides for their efﬁcacy in GRPR-targeted radiother-
apy of prostate cancer in preclinical models. Previous studies
have revealed a pronounced effect of the radiometal-chelate
on the biodistribution of RM26 in mice.12,13,30 Based on the
newly acquired in vitro and in vivo data we have concluded
that the tetra-aza chelators DOTAGA and DOTA resulted in
177Lu-radioligands with the most suitable properties for TRT,
showing a signiﬁcantly higher tumor uptake compared to the
NODAGA-carrying radioligand. This effect is most likely a result
of the lower bioavailability of the NODAGA-containing analog
due to its higher trapping in the pancreas and liver. 177Lu-
DOTAGA-PEG2-RM26 had the best in vivo stability and was cho-
sen for further evaluation.
In our further experiments, we focused on investigating
the factors that would increase tumor-to-kidneys dose ratio.
In general, renal toxicity is an important limitation for the
applicability of radiotracers for TRT. The stabilization in
peripheral blood by coinjection of the NEP-inhibitor PA
with 177Lu-DOTAGA-PEG2-RM26 resulted in an impres-
sive 60% ampliﬁcation of tumor uptake at 1 hr pi, due to
the higher supply of intact radioligand to the receptor-
expressing tumor cells. As expected, the uptake in GRPR-
expressing organs was also signiﬁcantly increased, while the
uptake in nontarget healthy tissues, particularly the kidneys
were not affected. This strategy has been successfully used
to enhance the efﬁcacy of other peptide-based targeting
vectors.31–33
An additional strategy for improving the ratio of tumor to kid-
ney absorbed dose is to identify the optimal peptide mass. By
gradually increasing the injected peptide dose, we observed a
strong blocking effect on the tumor and the GRPR-expressing
organs, but not in the kidneys and normal organs devoid of
GRPR-expression. This observation contradicts with previously
reported data for the similar GRPR antagonist RM228 and for
GRPR agonists.34 In both cases, tumor uptake was not inﬂuenced
by peptide dose and remained stable up to 250–500 pmol. Inter-
estingly, autoradiography of tumor samples provided a remark-
able discovery: despite the highest tumor uptake, radioactivity
distribution was concentrated primarily in the rim of tumors for
the mice injected with 50 pmol. In contrast, tumor penetration
was signiﬁcantly better for the mice injected with 100 pmol and
above. This phenomenon can be explained by the “Binding Site
Barrier” model.35 This model predicts that high-afﬁnity binders
at a given dose tend to have limited diffusion into tumors and by
increasing the binder dose, a better percolation and more uniform
distribution can be achieved. Efﬁcient penetration into solid
tumors is essential for improved therapeutic efﬁcacy, especially
when using 177Lu that has a maximum penetration range in tissue
of 2 mm.
Biodistribution results of 177Lu-DOTAGA-PEG2-RM26
(100 pmol) revealed a rapid clearance from blood, kidneys
and normal nontarget organs. Tumor activity also cleared
relatively fast within the ﬁrst 24 hr pi. Nevertheless, tumor-to-
kidney ratios were higher than 2 at all time-points. Simula-
tions of injected peptide dose revealed that increase of injected
peptide mass up to 200 pmol caused only 16% decrease in
tumor-to-kidney ratios (Supporting Information Fig. S2B).
Based on this data, we designed a treatment protocol with
multiple injections of radiopeptide to overcome the rapid wash-
out of activity from tumors and performed an in vivo therapy
study. In the present study, we demonstrated the potential of
177Lu-DOTAGA-PEG2-RM26 for targeted radiotherapy of
prostate cancer. Tumor growth was signiﬁcantly delayed in the
groups treated with 177Lu-DOTAGA-PEG2-RM26. A decrease
in tumor volume was observed already after three therapy
cycles in the groups treated with radiolabeled peptide. Due to
the inhibition of tumor growth, median survival was also signif-
icantly longer in these groups. Importantly, the increased sur-
vival was not associated with any detected side effects.
The most interesting ﬁnding of our study was the signiﬁ-
cant improvement of overall survival in the group treated with
radiolabeled peptide plus trastuzumab. The HER2 protein is a
notorious proto-oncogene that was shown to be implicated in
a number of different cancers. In contrast to other cancers,
HER2 is not considered a major driver of prostate cancer pro-
gression. The expression level of this receptor is generally low
in prostate cancer. In the PC-3 tumor model used in our
study, HER2-expression (~25,000 receptors/cell36) could be
clinically considered as 1+ and HER2-targeted therapy alone
is unlikely to inhibit tumor growth. Nonetheless, HER2 may
have an important role as a resistance mechanism to other
therapies. HER2 was found to be activated in prostate cancer
after hormone therapy and patients suffering from metastatic
prostate cancer were generally found to have higher levels of
serum HER2 compared to those with early nonmetastatic dis-
ease.37 In a recent in vitro study, Andersson et al. showed that
HER2 expression in PC-3 cells increased signiﬁcantly after
external irradiation leading to resistance to therapy.20
Trastuzumab (Herceptin®) is an anti-HER2 antibody
which has complex cytostatic action and is used for the treat-
ment of HER2-positive breast cancers.38 Trastuzumab alone
does not give any therapeutic beneﬁts to HER2-negative
patients or patients with low HER2 expression. To increase
treatment output, trastuzumab therapy is often combined with
nonanthracycline-based chemotherapy and endocrine therapy.
More recently trastuzumab–emtansine, an antibody–drug con-
jugate that combines the antitumor properties of trastuzumab
with the cytotoxic effects of a microtubule-disrupting chemo-
therapy drug mertansine, was introduced.
In our study, the coinjection of trastuzumab together with
the radiolabeled peptide signiﬁcantly improved the overall
survival. In agreement with clinical data, antiHER2 treatment
did not induce any measurable therapeutic effect, however,
3356 Trastuzumab improves prostate cancer targeted radiotherapy
Int. J. Cancer: 145, 3347–3358 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
C
an
ce
r
T
he
ra
py
an
d
P
re
ve
n
ti
on
IHC HER2 staining demonstrated that even short treatment
with trastuzumab eliminated HER2 expression. Interestingly,
in agreement with our in vitro data,20 HER2 expression
increased shortly after radiotherapy in the group treated with
the radiopeptide but was not detected in the group treated
with the combination of radiopeptide and trastuzumab. The
absence of HER2 expression shortly after therapy could be
attributed to continued saturation of HER2 with trastuzumab.
However, the absence of HER2 expression was conﬁrmed in
these groups at the endpoint.
Taking into account that trastuzumab has a complex mecha-
nism of action on HER2-expressing cells, it is difﬁcult to pinpoint
the particular mechanism that is involved in this radiosensitizing
effect. We could speculate that blocking of HER2 with
trastuzumab decreased the repairing ability of irradiated cells.
This ﬁnding is in agreement with a recent study demonstrating
that the effect of GRPR-targeted TRT of prostate cancer increases
when combined with mTOR inhibitor rapamycin.28
The clinical use of trastuzumab has been ﬁrmly established in
the clinics over the past decades either as monotherapy or in
combination with established cytostatic drugs or other targeted
substances. The wide range of therapeutic combinations and
good tolerability of trastuzumab should facilitate its implementa-
tion with TRT and external irradiation, not only in the treatment
of prostate cancer but also for other cancers that are often treated
with external beam therapy or TRT with the precondition that
lesions express HER2. In a recent study, HER2 overexpression
was detected in 2.7% of tissue samples collected from 37,992
patients suffering from different malignancies. HER2 over-
expression was detected in bladder carcinomas (12.4%), gallblad-
der carcinomas (9.8%), extrahepatic cholangiocarcinomas (6.3%)
or cervical carcinomas (3.9%).39 Detection of HER2 could be con-
ﬁrmed either with IHC analysis of biopsy material or by molecu-
lar imaging using HER2-targeting probes. A recent clinical study
demonstrated that even low HER2 expression could be detected
using 68Ga-ABY-025, the anti-HER2 afﬁbody molecule used in
our study.40
In conclusion, we have developed and characterized a promis-
ing GRPR-targeting radioligand 177Lu-DOTAGA-PEG2-RM26
and demonstrated its therapeutic efﬁcacy in vivo in prostate can-
cer xenografts. Moreover, our study presents the ﬁrst in vivo
proof-of-principle that the effects of anti-GRPR radiotherapy can
be ampliﬁed by coadministration of anti-HER2 treatment leading
to prolonged survival.
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